[{"id":"2ab3be78-da97-4157-b13f-eceb7d0e0e2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448042","created_at":"2021-01-18T17:00:06.345Z","updated_at":"2024-07-02T16:35:10.189Z","phase":"Phase 1","brief_title":"A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","source_id_and_acronym":"NCT03448042","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • Actemra IV (tocilizumab) • runimotamab (RG6194)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 537","initiation":"Initiation: 06/06/2018","start_date":" 06/06/2018","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-04-11"}]